

# 2025年度 财政报告

**Thong Chai Institute of Medical Research**  
(Company Registration Number: 200311661W)  
(Registered under Companies Act 1967 and Charities Act 1994)

**AUDITED FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2025**



26 Eng Hoon Street Singapore 169776  
Tel: 6533 7393 Fax: 6533 6831  
[www.tanchan-cpa.com](http://www.tanchan-cpa.com)

**Thong Chai Institute of Medical Research**  
(Company Registration Number: 200311661W)

**AUDITED FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2025**

---

<b>Contents</b>	<b>Page</b>
Directors' Statement	1 – 2
Independent Auditor's Report	3 – 5
Statement of Financial Position	6
Statement of Financial Activities	7 – 8
Statement of Changes in Funds	9
Statement of Cash Flows	10
Notes to the Financial Statements	11 – 28

**Thong Chai Institute of Medical Research**  
**DIRECTORS' STATEMENT**  
**For the Financial Year Ended 31 December 2025**

---

The directors are pleased to present their statement to the members together with the audited financial statements of Thong Chai Institute of Medical Research (the "Company") for the financial year ended 31 December 2025.

In the opinion of the directors,

- (a) the financial statements of the Company are drawn up so as to give a true and fair view of the financial position of the Company as at 31 December 2025 and of the financial performance, changes in funds and cash flows of the Company for the year ended 31 December 2025 in accordance with the provisions of the Companies Act 1967 (the "Companies Act"), the Charities Act 1994 and other relevant regulations (the "Charities Act and Regulations") and Financial Reporting Standards in Singapore ("FRSs"); and
- (b) at the date of this statement, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they fall due.

**DIRECTORS**

The directors of the Company in office at the date of this statement are:

Yeo Eng Koon  
Teo Kek Tjok @ Teo Kek Yeng  
Lim Tiang Chuan  
Kwa Soon Yau @ Kwa Eng Giap  
Low Theng Whee  
Teo Kok Keong  
Lim Hwee Hai  
Lee Peng Shu  
Zheng Huangfang  
Lee Chia Khee  
Quek Su-An  
Loh Kim Gek  
Lim Weihan (Lin Weihan)  
Khoo Boo Liat  
Goh Xin Yi  
Shen Renyuan  
Leow Xin Ting, Kimberly  
Wong Chiah Yuen  
Tiew Chong Hui, Grace  
Chua Shin Yoong  
Quek Yi Yang Eugene

**Thong Chai Institute of Medical Research**

**DIRECTORS' STATEMENT  
For the Financial Year Ended 31 December 2025**

---

**DIRECTORS' INTEREST IN SHARES OR DEBENTURES, ARRANGEMENTS TO  
ENABLE DIRECTORS TO ACQUIRE SHARES AND DEBENTURES**

As the Company is limited by guarantee and has no share capital or debentures, the statutory information required to be disclosed by the directors under Schedule 12(8)(a) and Schedule 12(8)(b) of the Companies Act 1967 does not apply.

The liability of each member is limited to \$1 while he/she is a member, or within one year after he/she ceases to be a member.

At the end of reporting date, the Company has a total of 83 (2024: 95) members.

**INDEPENDENT AUDITOR**

The independent auditor, Tan, Chan & Partners, has expressed its willingness to accept re-appointment as auditor.

On behalf of the Board of Directors

Yeo Eng Koon  
Director

Lim Hwee Hai  
Director

Singapore

Date: 20 March 2026

## INDEPENDENT AUDITOR'S REPORT

To the Members of  
**Thong Chai Institute of Medical Research**  
For the Financial Year Ended 31 December 2025

---

### Report on the Audit of the Financial Statements

#### *Opinion*

We have audited the financial statements of Thong Chai Institute of Medical Research (the "Company"), which comprise the statement of financial position as at 31 December 2025, and the statement of financial activities, statement of changes in funds and statement of cash flows for the financial year then ended, and notes to the financial statements, including material accounting policy information.

In our opinion, the accompanying financial statements are properly drawn up in accordance with the provisions of the Companies Act 1967 (the "Act"), the Charities Act 1994 and other relevant regulations (the "Charities Act and Regulations") and Financial Reporting Standards in Singapore ("FRSs") so as to give a true and fair view of the financial position of the Company as at 31 December 2025 and of the financial performance, changes in funds and cash flows of the Company for the year ended on that date.

#### *Basis for Opinion*

We conducted our audit in accordance with Singapore Standards on Auditing ("SSAs"). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Accounting and Corporate Regulatory Authority ("ACRA") Code of Professional Conduct and Ethics for Public Accountants and Accounting Entities ("ACRA Code") together with the ethical requirements that are relevant to our audit of the financial statements in Singapore, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ACRA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### *Other Information*

Management is responsible for the other information. The other information comprises the information included in the Directors' Statement and the annual report, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

## INDEPENDENT AUDITOR'S REPORT

To the Members of  
**Thong Chai Institute of Medical Research**  
For the Financial Year Ended 31 December 2025

---

### Report on the Audit of the Financial Statements (Cont'd)

#### *Responsibilities of Management and Directors for the Financial Statements*

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the provisions of the Act, the Charities Act and Regulations and FRSSs, and for devising and maintaining a system of internal accounting controls sufficient to provide a reasonable assurance that assets are safeguarded against loss from unauthorised use or disposition, and transactions are properly authorised and that they are recorded as necessary to permit the preparation of true and fair financial statements and to maintain accountability of assets.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The directors' responsibilities include overseeing the Company's financial reporting process.

#### *Auditor's Responsibilities for the Audit of the Financial Statements*

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SSAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SSAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

## INDEPENDENT AUDITOR'S REPORT

To the Members of  
**Thong Chai Institute of Medical Research**  
For the Financial Year Ended 31 December 2025

---

### Report on the Audit of the Financial Statements (Cont'd)

#### *Auditor's Responsibilities for the Audit of the Financial Statements (Cont'd)*

As part of an audit in accordance with SSAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also: (cont'd)

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

### Report on Other Legal and Regulatory Requirements

In our opinion, the accounting and other records required by the Act to be kept by the Company have been properly kept in accordance with the provisions of the Act, and the Charities Act and Regulations.

During the course of our audit, nothing has come to our attention that causes us to believe that during the financial year:

- (a) the Company has not used the donation moneys in accordance with its objectives as required under Regulation 11 of the Charities (Institutions of a Public Character) Regulations; and
- (b) the Company has not complied with the requirement of Regulation 15 of the Charities (Institutions of a Public Character) Regulations.

*Tan, Chan & Partners*

**Tan, Chan & Partners**  
*Public Accountants and  
Chartered Accountants*

Singapore

Date: 20 March 2026

**Thong Chai Institute of Medical Research**

**STATEMENT OF FINANCIAL POSITION**  
As at 31 December 2025

	Note	2025 \$	2024 \$
<b>ASSETS</b>			
<b>Non-current asset</b>			
Plant and equipment	4	-	133
<b>Current assets</b>			
Other receivables	5	327,128	88,062
Cash and cash equivalents	6	6,607,340	5,972,131
		<u>6,934,468</u>	<u>6,060,193</u>
<b>Total assets</b>		<u><u>6,934,468</u></u>	<u><u>6,060,326</u></u>
<b>LIABILITIES AND FUNDS</b>			
<b>Current liability</b>			
Other payables	7	6,059	4,480
<b>Funds</b>			
<u>Unrestricted Funds</u>			
Non-designated:			
-General Fund		2,743,117	2,081,647
Designated:			
-Sim Foundation (Education Fund)	8	1,447,457	1,372,922
-Government Matching Grant Fund	9	1,168,679	1,026,252
<u>Restricted Fund</u>			
Medical Research Fund	10	1,569,156	1,575,025
		<u>6,928,409</u>	<u>6,055,846</u>
<b>Total liabilities and funds</b>		<u><u>6,934,468</u></u>	<u><u>6,060,326</u></u>

*The accompanying notes form an integral part of the financial statements.*

**Thong Chai Institute of Medical Research**

**STATEMENT OF FINANCIAL ACTIVITIES  
For the Financial Year Ended 31 December 2025**

	Note	Unrestricted			Restricted Medical Research Fund	Total Funds
		General Fund	Sim Foundation (Education Fund)	Government Matching Grant Fund		
		\$	\$	\$	\$	\$
<b>Income from generated funds</b>						
Voluntary income						
Donations	15	434,312	-	-	-	434,312
Income from charitable activities	11	134,152	127,949	-	-	262,101
Other income	12	128,783	-	250,000	-	378,783
<b>Total income</b>		<b>697,247</b>	<b>127,949</b>	<b>250,000</b>	<b>-</b>	<b>1,075,196</b>
<b>Less: Cost of charitable activities</b>						
	13	8,964	53,026	107,573	5,819	175,382
<b>Less: Governance and administrative expenses</b>						
	14	26,813	388	-	50	27,251
<b>Surplus/(Deficit) for the financial year, representing total comprehensive income/(loss) for the financial year</b>		<b>661,470</b>	<b>74,535</b>	<b>142,427</b>	<b>(5,869)</b>	<b>872,563</b>

*The accompanying notes form an integral part of the financial statements.*

**Thong Chai Institute of Medical Research**

**STATEMENT OF FINANCIAL ACTIVITIES (Cont'd)  
For the Financial Year Ended 31 December 2025**

	Note	Unrestricted			Total Funds
		General Fund	Sim Foundation (Education Fund)	Government Matching Grant Fund	
		\$	\$	\$	\$
2024					
Income from generated funds					
Voluntary income					
Donations	15	487,036	-	-	487,036
Income from charitable activities	11	103,678	137,086	-	240,764
Other income	12	188,109	-	250,000	438,109
Total income		778,823	137,086	250,000	1,165,909
Less: Cost of charitable activities	13	9,105	40,554	89,976	139,635
Less: Governance and administrative expenses	14	32,826	383	-	33,209
Surplus for the financial year, representing total comprehensive income for the financial year		736,892	96,149	160,024	993,065

*The accompanying notes form an integral part of the financial statements.*

**Thong Chai Institute of Medical Research**

**STATEMENT OF CHANGES IN FUNDS  
For the Financial Year Ended 31 December 2025**

	Non-designated	Designated		Restricted Medical Research Fund	Total Funds
		Sim Foundation (Education Fund)	Government Matching Grant Fund		
	\$	\$	\$	\$	\$
As at 1 January 2024	1,344,755	1,276,773	866,228	1,575,025	5,062,781
Surplus for the financial year, representing total comprehensive income for the financial year	736,892	96,149	160,024	-	993,065
As at 31 December 2024	2,081,647	1,372,922	1,026,252	1,575,025	6,055,846
Surplus/(Deficit) for the financial year, representing total comprehensive income/(loss) for the financial year	661,470	74,535	142,427	(5,869)	872,563
<b>As at 31 December 2025</b>	<b>2,743,117</b>	<b>1,447,457</b>	<b>1,168,679</b>	<b>1,569,156</b>	<b>6,928,409</b>

*The accompanying notes form an integral part of the financial statements.*

**Thong Chai Institute of Medical Research**  
**STATEMENT OF CASH FLOWS**  
**For the Financial Year Ended 31 December 2025**

	Note	2025 \$	2024 \$
<b>Cash flows from operating activities</b>			
Surplus for the financial year		872,563	993,065
<u>Adjustments for:</u>			
Depreciation of plant and equipment	4	133	320
Fixed deposit interest income	12	(127,467)	(168,386)
Operating cash flows before working capital changes		<u>745,229</u>	<u>824,999</u>
<u>Change in working capital:</u>			
Prepayment		-	5,762
Other receivables		(268,950)	(9,960)
Other payables		1,579	620
Cash generated from operations		<u>477,858</u>	821,421
Fixed deposit interest received		<u>157,351</u>	158,053
<b>Net cash generated from operating activities</b>		<u><u>635,209</u></u>	<u><u>979,474</u></u>
<b>Net increase in cash and cash equivalents</b>		<b>635,209</b>	979,474
<b>Cash and cash equivalents at beginning of financial year</b>		<u><u>5,972,131</u></u>	<u><u>4,992,657</u></u>
<b>Cash and cash equivalents at end of financial year</b>	6	<u><u><u>6,607,340</u></u></u>	<u><u><u>5,972,131</u></u></u>

*The accompanying notes form an integral part of the financial statements.*

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2025**

---

These notes form an integral part of and should be read in conjunction with the accompanying financial statements.

**1. GENERAL INFORMATION**

Thong Chai Institute of Medical Research (the “Company”) is incorporated and domiciled in the Republic of Singapore, limited by guarantee and not having a share capital. The Company is registered as a charity under the Charities Act 1994 and is an approved Institution of Public Character (IPC) from 18 April 2025 to 17 April 2028.

The registered office and its principal place of operation is located at 50 Chin Swee Road, #01-02, Thong Chai Building, Singapore 169874.

The principal activities of the Company are those of research and experimental development on medical technologies, health services and to do all such other things as may be deemed incidental or conducive to the attainment of the objective of providing medical course training.

The Company had 83 (2024: 95) members at the end of the reporting year.

The financial statements of the Company for the financial year ended 31 December 2025 were authorised for issue by the Board of Directors on date of the Directors’ Statement.

**2. MATERIAL ACCOUNTING POLICY INFORMATION**

**2.1 Basis of preparation**

The financial statements have been prepared in accordance with Financial Reporting Standards in Singapore (“FRSs”) under the historical cost convention, except as disclosed in the accounting policies below.

The financial statements of the Company are presented in Singapore Dollar (“\$”), which is the Company’s functional currency.

**2.2 Adoption of new and amended standards and interpretations**

The accounting policies adopted are consistent with those of the previous financial year except that in the current financial year, the Company has adopted all the new and revised standards which are effective for annual financial periods beginning on or after 1 January 2025. The adoption of these new/revised standards and interpretations did not have any material effect on the financial performance or position of the Company.

**2.3 Standards issued but not yet effective**

A number of new standards and amendments to standard that have been issued are not yet effective and have not been applied in preparing these financial statements.

The directors expect that the adoption of these new and amended standards will have no material impact on the financial statements in the year of initial application.

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2025**

---

**2. MATERIAL ACCOUNTING POLICY INFORMATION (Cont'd)**

2.4 Foreign currency transactions and balances

Transactions in foreign currencies are measured in the functional currency of the Company and are recorded on initial recognition in the functional currency at exchange rates approximating those ruling at the transaction dates. Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange ruling at the reporting date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates as at the dates of the initial transactions.

Exchange differences arising on the settlement of monetary items or on translating monetary items at the end of the reporting period are recognised in statement of financial activities.

2.5 Plant and equipment

All items of plant and equipment are initially recorded at cost. Subsequent to initial recognition, plant and equipment are measured at cost less accumulated depreciation and any accumulated impairment losses. The cost of plant and equipment comprises its purchase price and any directly attributable costs of bringing the asset to working condition for its intended use.

Depreciation is computed on a straight-line method over the estimated useful lives of the assets as follows:

	<u>Estimated useful life</u>
Computers	5 years

Fully depreciated plant and equipment are retained in the financial statements until they are no longer in use and no further charge for depreciation is made in respect of these assets.

The carrying values of plant and equipment are reviewed for impairment when events or changes in circumstances indicate that the carrying value may not be recoverable.

The residual value, estimated useful lives and depreciation method are reviewed at each reporting period and adjusted prospectively, if appropriate.

An item of plant and equipment is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising from derecognition of the assets is included in statement of financial activities in the period that the assets are derecognised.

2.6 Impairment of non-financial assets

The Company assesses at each reporting date whether there is an indication that an asset may be impaired. If any such indication exists, or when annual impairment assessment for an asset is required, the Company makes an estimate of the asset's recoverable amount.

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2025**

---

**2. MATERIAL ACCOUNTING POLICY INFORMATION (Cont'd)**

**2.6 Impairment of non-financial assets (cont'd)**

An asset's recoverable amount is the higher of an asset's or cash-generating unit's fair value less costs to sell and its value in use and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets. In assessing value in use, the estimated future cash flows expected to be generated by the asset are discounted to their present value. Where the carrying amount of an asset exceeds its recoverable amount, the asset is considered impaired and written down to its recoverable amount.

Impairment losses are recognised in statement of financial activities.

A previously recognised impairment loss is reversed only if there has been a change in the estimates used to determine the asset's recoverable amount since the last impairment loss was recognised. If that is the case, the carrying amount of the asset is increased to its recoverable amount. That increase cannot exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised previously. Such reversal is recognised in the statement of financial activities.

**2.7 Financial instruments**

**(a) Financial assets**

Initial recognition and measurement

Financial assets are recognised when, and only when the entity becomes party to the contractual provisions of the instruments.

At initial recognition, the Company measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit and loss ("FVPL"), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVPL are expensed in the statement of financial activities.

Subsequent measurement

*Investments in debt instruments*

Subsequent measurement of debt instruments depends on the Company's business model for managing the asset and the contractual cash flow characteristics of the asset. The three measurement categories for classification of debt instruments are amortised cost, fair value through other comprehensive income ("FVOCI") and FVPL. The Company only has debt instruments at amortised cost.

Financial assets that are held for the collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortised cost. Financial assets are measured at amortised cost using the effective interest method, less impairment. Gains and losses are recognised in the statement of financial activities when the assets are derecognised or impaired, and through the amortisation process.

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2025**

---

**2. MATERIAL ACCOUNTING POLICY INFORMATION (Cont'd)**

2.7 Financial instruments (cont'd)

(a) Financial assets (cont'd)

Derecognition

A financial asset is derecognised where the contractual right to receive cash flows from the asset has expired. On derecognition of a financial asset in its entirety, the difference between the carrying amount and the sum of the consideration received and any cumulative gain or loss that had been recognised in other comprehensive income for debt instruments is recognised in the statement of financial activities.

(b) Financial liabilities

Initial recognition and measurement

Financial liabilities are recognised when, and only when, the Company becomes a party to the contractual provisions of the financial instrument. The Company determines the classification of its financial liabilities at initial recognition.

All financial liabilities are recognised initially at fair value plus in the case of financial liabilities not at FVPL, net of directly attributable transaction costs.

Subsequent measurement

After initial recognition, financial liabilities that are not carried at FVPL are subsequently measured at amortised cost using the effective interest method. Gains and losses are recognised in the statement of financial activities when the liabilities are derecognised, and through the amortisation process.

Derecognition

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. On derecognition, the difference between the carrying amounts and the consideration paid is recognised in the statement of financial activities.

2.8 Impairment of financial assets

The Company recognises an allowance for expected credit losses (“ECLs”) for all debt instruments not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2025**

---

**2. MATERIAL ACCOUNTING POLICY INFORMATION (Cont'd)**

**2.8 Impairment of financial assets (cont'd)**

ECLs are recognised in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is recognised for credit losses expected over the remaining life of the exposure, irrespective of timing of the default (a lifetime ECL).

The Company considers a financial asset in default when internal or external information indicates that the Company is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Company. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.

**2.9 Cash and cash equivalents**

Cash and cash equivalents comprise cash at bank, cash on hand and fixed deposits which are subject to an insignificant risk of changes in value.

**2.10 Provisions**

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and the amount of the obligation can be estimated reliably.

Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate. If it is no longer probable that an outflow of resources embodying economic benefits will be required to settle the obligation, the provision is reversed. If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, where appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

**2.11 Employee benefits**

Defined contribution plan

The Company makes contribution to the Central Provident Fund scheme in Singapore, a defined contribution pension scheme. Contributions to this national pension scheme are recognised as an expense in the period in which the related service is performed.

Short-term benefits

All short-term benefits are recognised in statement of financial activities in the period in which the employees rendered their services to the Company.

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2025**

---

**2. MATERIAL ACCOUNTING POLICY INFORMATION (Cont'd)**

2.12 Income recognition

Income is measured based on the consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to customers, excluding amounts collected on behalf of third parties.

Income is recognised when the Company satisfies a performance obligation by transferring a promised good or service to the customers, which is when the customers obtain control of the good or service. A performance obligation may be satisfied at a point in time or over time. The amount of income recognised is the amount allocated to the satisfied performance obligation.

*(a) Donations*

Donations are recognised at a point in time.

*(b) Course fees, CPE and seminar income*

Revenue from course fees and seminar income are recognised over a period of time based on the term of course and seminar.

*(c) Research and Development ("R&D") income*

Yi Shi Yuan Pte Ltd produces the BSYJ 120 & BSYJ 500 based on the prescriptions given by the Company which was specified in the collaboration agreement. R&D income is the payment received from Yi Shi Yuan Pte Ltd based on the sales volume sold multiplied with agreed rates (BSYJ 120 capsules @ \$8 & BSYJ 500 capsules @ \$24).

Revenue relating to research and development is recognised at a point in time.

*(d) Interest income*

Interest income is recognised using the effective interest method over a period of time.

*(e) Other miscellaneous income*

Other miscellaneous income is recognised at a point in time.

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2025**

---

**2. MATERIAL ACCOUNTING POLICY INFORMATION (Cont'd)**

2.13 Contingencies

A contingent liability is:

- (a) a possible obligation that arises from past events whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company; or
- (b) a present obligation that arises from past events but is not recognised because:
  - (a) it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation; or
  - (b) the amount of the obligation cannot be measured with sufficient reliability.

A contingent asset is a possible asset that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company.

2.14 Government grants

Government grants are recognised as a receivable when there is reasonable assurance that the grant will be received and all attached conditions will be complied with.

When the grant relates to an expense item, it is recognised as income on a systematic basis over the periods that the related costs, for which it is intended to compensate, are expensed. When the grant relates to an asset, the fair value is recognised as deferred income on the statement of financial position and is recognised as income in equal amounts over the expected useful life of the related asset.

When loans or similar assistance are provided by governments or related institutions with an interest rate below the current applicable market rate, the effect of this favorable interest is regarded as additional government grant.

**3. SIGNIFICANT ACCOUNTING JUDGEMENTS AND ESTIMATES**

The preparation of the Company's financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of the revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities at the end of reporting period. Uncertainty about these assumptions and estimates could result in outcomes that could require a material adjustment to the carrying amount of the asset or liability affected in the future periods.

Management is of the opinion that there is no significant judgement made in applying accounting policies, and no estimation uncertainty that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial period.

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2025**

**4. PLANT AND EQUIPMENT**

	Note	Computers \$
<b><u>Cost</u></b>		
As at 1 January 2024, 31 December 2024 and 31 December 2025		<b>1,600</b>
<b><u>Accumulated depreciation</u></b>		
As at 1 January 2024		1,147
Depreciation	14	320
As at 31 December 2024		1,467
Depreciation	14	133
<b>As at 31 December 2025</b>		<b>1,600</b>
<b><u>Carrying amount</u></b>		
As at 31 December 2024		133
<b>As at 31 December 2025</b>		<b>-</b>

**5. OTHER RECEIVABLES**

	2025 \$	2024 \$
Fixed deposits interest receivables	26,026	55,910
Deposit	6,000	-
Grant receivable	250,000	-
Sundry receivables	45,102	32,152
	<b>327,128</b>	<b>88,062</b>

The non-trade sundry receivables are unsecured, interest-free and receivable on demand.

**6. CASH AND CASH EQUIVALENTS**

	2025 \$	2024 \$
Cash at bank	600,447	622,449
Cash on hand	241	380
Fixed deposits	6,006,652	5,349,302
	<b>6,607,340</b>	<b>5,972,131</b>

Fixed deposits were placed at tenor of 6 months (2024: 1 to 12 months) and earned interest ranging from 1.15% to 1.60% (2024: at 3.11%) per annum.

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2025**

**7. OTHER PAYABLES**

	2025	2024
	\$	\$
Accruals	4,538	4,000
Advance membership fee	410	480
Other payables	1,111	-
	6,059	4,480

**8. SIM FOUNDATION (EDUCATION FUND)**

It is established to support the expenses incurred for conducting the Continuing Professional Education (CPE) Programs for TCM Practitioners. The expenses comprise lecturers'/ speakers' fees, CPE allowance, venue fees, and other related expenses in connection with the CPE courses.

**9. GOVERNMENT MATCHING GRANT FUND**

Government Matching Grant Fund is established to provide scholarships and sponsorships for Nanyang Technological University students and postgraduate students respectively to enable them to continue with their studies in Traditional Chinese Medicine at the university.

**10. MEDICAL RESEARCH FUND**

Medical Research Fund was originally established by Singapore Thong Chai Medical Institution for the medical research and further education and training for Traditional Chinese Physicians in the field of Traditional Chinese Medicine.

Thong Chai Institute of Medical Research was incorporated to undertake the role for the designated purpose. Accordingly, pursuant to the constitution and rules, the fund was transferred to Thong Chai Institute of Medical Research on 23 October 2008.

**Thong Chai Institute of Medical Research**

**NOTES TO THE FINANCIAL STATEMENTS**  
For the Financial Year Ended 31 December 2025

**11. INCOME FROM CHARITABLE ACTIVITIES**

	2025		2025		2025		2024		2024	
	Non-designated	Designated Sim Foundation (Education Fund)	Total Funds	Non-designated	Designated Sim Foundation (Education Fund)	Total Funds	Non-designated	Designated Sim Foundation (Education Fund)	Total Funds	
	\$		\$		\$		\$		\$	
CPE income	-	40,941	40,941	-	60,082	60,082	-	60,082	60,082	
CPE short training course income	-	85,908	85,908	-	77,004	77,004	-	77,004	77,004	
Course fee	300	-	300	-	-	-	-	-	-	
Course administrative fee	3,900	-	3,900	2,100	-	2,100	-	-	2,100	
NUS demonstration sessions	4,800	-	4,800	4,780	-	4,780	-	-	4,780	
NTU clinical internship fee	37,530	-	37,530	39,870	-	39,870	-	-	39,870	
Public talk income	-	1,100	1,100	-	-	-	-	-	-	
R&D income	87,622	-	87,622	56,928	-	56,928	-	-	56,928	
	<b>134,152</b>	<b>127,949</b>	<b>262,101</b>	<b>103,678</b>	<b>137,086</b>	<b>240,764</b>				

**Thong Chai Institute of Medical Research**

**NOTES TO THE FINANCIAL STATEMENTS  
For the Financial Year Ended 31 December 2025**

**12. OTHER INCOME**

	2025		2025		2025		2024		2024	
	Non-designated	Designated	Non-designated	Designated	Non-designated	Designated	Non-designated	Designated	Non-designated	Designated
	General Fund	Government Matching Grant Fund	General Fund	Government Matching Grant Fund	General Fund	Government Matching Grant Fund	General Fund	Government Matching Grant Fund	General Fund	Government Matching Grant Fund
	\$		\$		\$		\$		\$	
	2025		2025		2024		2024		2024	
	Total Funds		Total Funds		Total Funds		Total Funds		Total Funds	
Fixed deposits interest income	127,467	-	127,467	-	168,386	-	168,386	-	168,386	-
Membership fees	1,314	-	1,314	-	1,124	-	1,124	-	1,124	-
Miscellaneous income	2	-	2	-	137	-	137	-	137	-
Grant income:	-	-	-	-	18,034	-	18,034	-	18,034	-
TCM Development Grant	-	-	-	-	-	250,000	-	250,000	-	250,000
Tote Board contribution	-	250,000	-	250,000	-	-	-	-	-	-
Progressive Wage Credit Scheme	-	-	-	-	428	-	428	-	428	-
	<b>128,783</b>	<b>250,000</b>	<b>378,783</b>	<b>250,000</b>	<b>188,109</b>	<b>250,000</b>	<b>438,109</b>	<b>250,000</b>	<b>438,109</b>	<b>250,000</b>

**Thong Chai Institute of Medical Research**

**NOTES TO THE FINANCIAL STATEMENTS  
For the Financial Year Ended 31 December 2025**

**13. COST OF CHARITABLE ACTIVITIES**

	Non-designated	Designated		Restricted	2025		Total Funds
		Sim Foundation (Education Fund)	Government Matching Grant Fund		2025	2025	
	2025	2025	2025	2025	2025	2025	2025
	\$	\$	\$	\$	\$	\$	\$
CPE expenses	-	8,420	-	-	-	8,420	8,420
CPE short training course expenses	-	44,326	-	-	-	44,326	44,326
Clinical teaching expenses	8,964	-	-	-	-	8,964	8,964
Public talk expenses	-	280	-	-	-	280	280
Research expenses	-	-	-	5,819	-	5,819	5,819
Scholarships	-	-	76,000	-	-	76,000	76,000
Sponsorships	-	-	31,573	-	-	31,573	31,573
	<b>8,964</b>	<b>53,026</b>	<b>107,573</b>	<b>5,819</b>	<b>5,819</b>	<b>175,382</b>	<b>175,382</b>

  

	Non-designated	Designated		Total Funds
		Sim Foundation (Education Fund)	Government Matching Grant Fund	
	2024	2024	2024	2024
	\$	\$	\$	\$
CPE expenses	-	8,649	-	8,649
CPE short training course expenses	-	31,905	-	31,905
Clinical teaching expenses	9,105	-	-	9,105
Public talk expenses	-	-	-	-
Research expenses	-	-	-	-
Scholarships	-	-	60,000	60,000
Sponsorships	-	-	29,976	29,976
	<b>9,105</b>	<b>40,554</b>	<b>89,976</b>	<b>139,635</b>

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2025**

**14. GOVERNANCE AND ADMINISTRATIVE COSTS**

	Non-designated	Designated	Restricted	
	General Fund	Sim Foundation (Education Fund)	Medical Research Fund	Total Funds
	\$	\$	\$	\$
<b>2025</b>				
Advertisement	827	-	-	827
Audit fee	6,713	-	-	6,713
Bank charges	286	-	-	286
Depreciation of plant and equipment	133	-	-	133
Entertainment	104	-	-	104
General expenses	11	-	-	11
Low value assets expenses off	11	-	-	11
Medical supplies	129	-	-	129
Postage, printing and stationery	5,748	-	-	5,748
Secretarial fee	450	-	-	450
Service fee	4,293	388	-	4,681
Software	785	-	-	785
Telephone charges	467	-	50	517
Trademark fee	2,345	-	-	2,345
Website design and maintenance	4,511	-	-	4,511
	<b>26,813</b>	<b>388</b>	<b>50</b>	<b>27,251</b>

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2025**

**14. GOVERNANCE AND ADMINISTRATIVE COSTS (Cont'd)**

	Note	Non-designated	Designated	Total Funds
		General Fund	Sim Foundation (Education Fund)	
		\$	\$	\$
<u>2024</u>				
Advertisement		827	-	827
Audit fee		4,691	-	4,691
Bank charges		398	-	398
Depreciation of plant and equipment	4	320	-	320
Entertainment		57	-	57
General expenses		176	-	176
General expenses (Flag Day)		1,552	-	1,552
Literature database		5,763	-	5,763
Low value assests expenses off		397	-	397
Membership fee		-	-	-
Repair and maintenance		120	-	120
Royalty fees		-	-	-
Secretarial fee		1,562	-	1,562
Service fee		5,858	383	6,241
Staff salaries and other related costs		-	-	-
Telephone charges		503	-	503
Trademark fee		880	-	880
Travelling expenses		3,491	-	3,491
Website design and maintenance		3,673	-	3,673
		<u>32,826</u>	<u>383</u>	<u>33,209</u>

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2025**

**15. DONATIONS**

	2025	2024
	\$	\$
Tax exempt donations	221,040	462,140
Non-tax exempt donations	213,272	24,896
	434,312	487,036
The donations were as follows:		
Donations	432,647	486,740
CDC Vouchers Scheme	1,665	296
	434,312	487,036

The qualifying donors enjoy concessionary tax treatment for donations made to the Company.

**16. TAXATION**

The Company was registered as an exempt charity under the Charities Act 1994 with effect from 5 January 2004. By virtue of Section 13(1)(zm) of the Income Tax Act 1947, the Company is exempted from income tax.

**17. FUND-RAISING**

30/70 Fund-raising Efficiency Ratio

	Note	2025	2024
		\$	\$
Income from fund-raising event	15	434,312	487,036
Fund raising expenses		9,434	11,571
Fund raising efficiency ratio		2.17%	2.38%

The fund-raising efficiency ratio has been computed as  $(E+S)/(R+S)$ , where **E** refers to the total expenses relating to fund-raising; **R** refers to the total gross receipts from fund-raising, other than receipts from sponsorships; and **S** refers to the total cost or value of sponsored goods and services relating to fund-raising.

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2025**

**18. COMMITMENTS**

Sponsorship and scholarship commitments

The Company has committed to provide scholarship and pay sponsorship to qualified students to pursue Traditional Chinese Medicine course. As at the reporting date, the scholarship and sponsorship committed for but not recognised as liabilities, are as follows:

	2025 \$	2024 \$
Not later than one year	68,690	51,526
Later than one year and not later than five years	33,897	13,013
	<u>102,587</u>	<u>64,539</u>

**19. RELATED PARTY TRANSACTIONS**

In addition to the related party transactions disclosed elsewhere in the financial statements, the Company carried out the following transactions with the related parties on terms agreed between the parties during the financial year:

	2025 \$	2024 \$
<u>Related party transactions with directors</u>		
- Sponsorship	3,369	3,407
- CPE expenses	-	420
- CPE short training course expenses	-	275
- Clinical teaching expenses	888	1,866
	<u>4,257</u>	<u>5,968</u>

**20. FAIR VALUE OF ASSETS AND LIABILITIES**

No financial assets or liabilities were measured at fair value as at financial year end.

The carrying amounts of financial assets and liabilities on the statement of financial position approximate their respective fair values due to the relatively short-term maturity of these financial instruments.

The directors consider that the carrying amounts of financial assets and liabilities recorded at amortised cost in the financial statements approximate their fair values.

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2025**

**21. FINANCIAL INSTRUMENTS**

At the reporting date, the aggregate carrying amounts of financial assets at amortised cost and financial liabilities at amortised cost were as follows:

	Note	2025 \$	2024 \$
<u>Financial assets</u>			
Other receivables	5	327,128	88,062
Cash and cash equivalents	6	<u>6,607,340</u>	<u>5,972,131</u>
<b>Financial assets at amortised cost</b>		<b><u>6,934,468</u></b>	<b><u>6,060,193</u></b>
<u>Financial liabilities</u>			
Other payables	7	6,059	4,480
<i>Less: Advance membership fee</i>	7	<u>(410)</u>	<u>(480)</u>
<b>Financial liabilities at amortised cost</b>		<b><u>5,649</u></b>	<b><u>4,000</u></b>

**22. FUNDS MANAGEMENT**

The primary objective of the Company's funds management is to ensure that the funding from members and other sources are properly managed and used to support its operations.

The Company manages its funds structure and makes adjustments to it, in light of changes in economic conditions. No changes were made to the objectives, policies or processes during the financial years ended 31 December 2025 and 2024 respectively.

The Company is not subjected to externally imposed capital requirements.

**23. FINANCIAL RISK MANAGEMENT**

The key financial risk faced by the Company is liquidity risk.

The Board of Directors is responsible for setting the objectives and underlying principles of financial risk management for the Company. The management team then establishes the detailed policies such as risk identification, measurement and exposure limits.

The finance personnel measure actual exposures against the limits set and prepare regular reports for the review of the management team and the Board of Directors. The information presented below is based on information received by key management.

Liquidity risk

Liquidity risk is the risk that the Company may encounter difficulties to settle or meet its financial obligations due to shortage of available funds. The Company's objective is to maintain sufficient level of cash and bank balances, and internally generated cash flows to finance its activities. The Company actively manages its operating cash flows and availability of funding so as to ensure that all repayment and funding needs are met.

All financial liabilities at the end of the reporting period are repayable within one year from the reporting date.

**Thong Chai Institute of Medical Research**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**For the Financial Year Ended 31 December 2025**

**24. RESERVE POLICY**

The Company will maintain adequate working capital to continue as a going concern as well as to extend its support base in order that it can develop and enhance its principal activities over the long term.

***Company's Reserves Position***

Reference:

	2025 \$	2024 \$	Increase/ (Decrease) %
(A) Unrestricted fund			
Accumulated fund	2,743,117	2,081,647	31.78
(B) Restricted and designated fund	4,185,292	3,974,199	5.31
(C) Endowment funds	-	-	N.M
(D) Total funds	6,928,409	6,055,846	14.41
(E) Annual operating expenditure	193,199	161,273	19.80
Ratio of funds to annual operating expenditure (A)/(E)	14.20	12.91	0.10

- (C) An endowment fund consists of assets, funds or properties, which are held in perpetuity, which produce annual income flow for a Company to spend as grants.
- (D) Total funds include unrestricted, restricted/ designated and endowment funds.
- (E) Total annual operating expenditure includes expenses related to cost of charitable activities and governance and other operating and administration expenditure, but exclude fund-raising expenses.

\*N.M: Not meaningful

The reserves of the Company provide financial stability and the means for development of the Company's activities. The Board intends to maintain the reserves at a level sufficient for its operating needs. The Company reviews the level of reserves regularly for the Company's continuing obligations.